{"id":1493,"date":"2022-04-12T02:32:33","date_gmt":"2022-04-12T00:32:33","guid":{"rendered":"http:\/\/serveur\/~onco-na\/?p=1493"},"modified":"2022-05-05T16:49:33","modified_gmt":"2022-05-05T14:49:33","slug":"syndrome-de-richter","status":"publish","type":"post","link":"https:\/\/essaisprecoces.onco-nouvelle-aquitaine.fr\/?p=1493","title":{"rendered":"Syndrome de Richter"},"content":{"rendered":"
\"image_pdf\"<\/a>\"image_print\"<\/a><\/div>\n\n\n\n
Pr\u00e9cisions localisation<\/th>\nPhase et Type d\u2019agent<\/th>\nPrincipaux crit\u00e8res cliniques<\/th>\nContacts r\u00e9f\u00e9rents<\/th>\n<\/tr>\n
Syndrome de Richter<\/td>\nPhase II<\/p>\n

Blinatumomab apr\u00e8s traitement de cytor\u00e9duction par R-CHOP<\/td>\n

\n
    \n
  • Diagnostic confirm\u00e9 de leuc\u00e9mie chronique lymphocytique ou lymphome \u00e0 petits lymphocytes selon le crit\u00e8re 19 iwCLL, avec biopsie prouvant la transformation en lymphome \u00e0 grandes cellules, coh\u00e9rant avec un syndrome de Richter (2016 WHO classification)\n<\/li>\n
  • Patient d\u00e9ja trait\u00e9 ou na\u00eff de tout traitement \u00e9ligible\n<\/li>\n
  • Age \u2265 18 ans\n<\/li>\n
  • ECOG \u2264 2\n<\/li>\n
  • Neutro \u2265 1,0 g\/l, plaquettes \u226550 g\/l en dehors de transfusion\n<\/li>\n
  • FEU gauche > 50 %\n<\/li>\n
  • Patient allogreff\u00e9 \u00e9ligible si GVH non significativement active et si greffe > 6 mois <\/li>\n<\/ul>\n<\/td>\n
\n